Troy Davidson
Researcher
Also affiliated: Arkansas Children's Hospital (2021)
Unknown Researcher
Research Areas
Biography and Research Information
OverviewAI-generated summary
Troy Davidson's research focuses on molecular mechanisms in pediatric acute megakaryoblastic leukemia. His recent publication investigates how epigenetic alterations in MED12L and ETO2-GLIS2 gene expression are associated with resistance to CDK8 inhibitors. This work contributes to understanding the cellular pathways that influence treatment efficacy in this specific type of leukemia.
Davidson has a current h-index of 2 based on four publications. He has collaborated with researchers at the University of Arkansas for Medical Sciences, including Samrat Roy Choudhury, Jordan T. Bird, Jason E. Farrar, and Stephanie D. Byrum, with whom he shares one publication each. His recent publication was in 2021, indicating ongoing activity in his research area.
Metrics
- h-index: 2
- Publications: 4
- Citations: 7
Selected Publications
-
Epigenetically Enhanced MED12L in ETO2-GLIS2 Positive Pediatric Acute Megakaryoblastic Leukemia Is Associated with Resistance to the CDK8 Inhibitors (2021)
Collaboration Network
Top Collaborators
- Epigenetically Enhanced MED12L in ETO2-GLIS2 Positive Pediatric Acute Megakaryoblastic Leukemia Is Associated with Resistance to the CDK8 Inhibitors
- Epigenetically Enhanced MED12L in ETO2-GLIS2 Positive Pediatric Acute Megakaryoblastic Leukemia Is Associated with Resistance to the CDK8 Inhibitors
- Epigenetically Enhanced MED12L in ETO2-GLIS2 Positive Pediatric Acute Megakaryoblastic Leukemia Is Associated with Resistance to the CDK8 Inhibitors
- Epigenetically Enhanced MED12L in ETO2-GLIS2 Positive Pediatric Acute Megakaryoblastic Leukemia Is Associated with Resistance to the CDK8 Inhibitors
- Epigenetically Enhanced MED12L in ETO2-GLIS2 Positive Pediatric Acute Megakaryoblastic Leukemia Is Associated with Resistance to the CDK8 Inhibitors
- Epigenetically Enhanced MED12L in ETO2-GLIS2 Positive Pediatric Acute Megakaryoblastic Leukemia Is Associated with Resistance to the CDK8 Inhibitors
- Epigenetically Enhanced MED12L in ETO2-GLIS2 Positive Pediatric Acute Megakaryoblastic Leukemia Is Associated with Resistance to the CDK8 Inhibitors
- Epigenetically Enhanced MED12L in ETO2-GLIS2 Positive Pediatric Acute Megakaryoblastic Leukemia Is Associated with Resistance to the CDK8 Inhibitors
- Epigenetically Enhanced MED12L in ETO2-GLIS2 Positive Pediatric Acute Megakaryoblastic Leukemia Is Associated with Resistance to the CDK8 Inhibitors
- Epigenetically Enhanced MED12L in ETO2-GLIS2 Positive Pediatric Acute Megakaryoblastic Leukemia Is Associated with Resistance to the CDK8 Inhibitors
Similar Researchers
Based on overlapping research topics